BIOGRAPHY
Leading Specialist in Urological Cancer
Professor Robert Huddart studied medicine at St Peter’s College, Oxford and at the University College/Middlesex Hospital, London before undertaking further general medical training in London, Oxford and Cambridge. He moved to The Royal Marsden in 1989 for specialist training in Clinical Oncology. He completed a PhD in the molecular biology of testicular cancer before completing his training at The Royal Marsden. He was appointed as Senior Lecturer and Honorary Consultant at the Institute of Cancer Research in 1996 being promoted to Reader in 2007 and Professor in 2015.
Professor Huddart has developed an international reputation in management of urological cancer with a particular focus on bladder and testicular cancer regularly speaking at major international meetings on these topics.
He leads the UK's largest testicular cancer network in the South East of England he has been involved in writing the National Institute of Health and Care Excellence (NICE) guidelines in the management of bladder cancer.
He is former chair of national testis research group and member of the bladder cancer study group . He is current CT RAD work stream chair and works on the NCRI bladder cancer localise and advanced study groups He has a led a number of major UK trials including BC2001, MRC TE23, 111 study, HYBRID and RAIDER
​
​
​
RADIOTHERAPY
Professor Huddart offers a wide range of radiotherapy treatments for the spectrum of urological cancer including Prostate, Bladder and Testicular cancer. He and his team pioneered Intensity modulated radiotherapy, image guided and adaptive radiotherapy. He is currently studying Magnetic Resonance guided radiotherapy (at the Royal Marsden Hospital). These techniques in addition to stereotactic radiotherapy are offered at either the Royal Marsden and Cancer Centre London
​
​
CHEMOTHERAPY
Professor Huddart is experienced in wide spectrum of drug therapy for urological cancer
Testicular cancer: BEP, Carboplatin and Salvage chemotherapy
Prostate Cancer: Full range of systemic therapies including Docetaxol, Carbazitazel, LHRH agonist, Abiraterone, Enzalutamide and Apalatumide
Bladder cancer: Chemotherapy and immunotherapy including Cisplatin/Gemcitabine, Pembroluzimab, Atezoluzimab and Vinflunine
RADIOACTIVE ISOTOPES
Radioactive isotopes are one of the newest treatments for advanced prostate cancer. Professor Huddart can offer both Radium 223 and Lutetium PSMA at Cancer Centre London
SECOND OPINIONS
Expert advice
Professor Huddart can offer second opinions at Cancer Centre London and Royal Marsden FT.
​
Remote Video Consultations can be arranged by prior discussion.
​
Insured patients should note that second opinions are not normally funded by insurance companies.
